In a follow-up examination of a randomized controlled trial, Brian A. Bergmark and colleagues discovered that among patients enrolled six to 12 months after an ACS, heightened FGF23 concentration was associated with an increased occurrence of a composite outcome, including ischemic episodes, heart failure, and all-cause mortality. The gene discussed is FGF23; the disease is heart failure.